Tumor Biology
1. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15.
2. Heufler C et al. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med 1993;178:1109-14.
3. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003;5:31-6.
4. Saji H et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92:1085-91.
5. Niwa Y et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9.
6. Tsukishiro S et al. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 2006;102:542-5.
7. Mocellin S et al. TNF and cancer: the two sides of the coin. Front Biosci 2008;13:2774-83.
8. Tomihara K et al. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther 2008;15:203-13.
9. Ottaiano A et al. CD40 activation as potential tool in malignant neoplasms. Tumori 2002;88:361-6.
10. Murugaiyan G et al. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J Immunol. 2007;178:2047-55.
11. Visco C et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006;77:387-94.
12. Breen EC et al. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006;27:187-94.
13. Nishioka C et al. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci 2005;96:810-5.
14. Hock BD et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 2004;45:2111-8.
15. Hock BD et al. Circulating levels and clinical significance of soluble CD86 in myeloma patients. Br J Haematol 2006;133:165-72.
16. Uner A et al. Serum levels of soluble E-selectin in colorectal cancer. Neoplasma 2004;51:269-74.
17. ShimadaY et al. High serum soluble E-selectin levels are associated with postoperative haematogenic recurrence in esophageal squamous cell carcinoma patients. Oncol Rep. 2003;10:991-5.
18. Shimada H et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003;83:248-52.
19. Lee JG et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 2008. (Epub ahead of print).
20. Morris-Stiff G et al. C-reactive protein in liver cancer surgery. Eur J Surg Oncol 2008;34:727-9.
21. Hefler LA et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008;14:710-4.
22. Yoshida S et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008;101:978-81.
23. Shiu YC et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum 2008;51:443-9.
24. Mroczko B et al. Hematopoietic cytokines as tumor markers. Clin Chem Lab Med 2004;42:1347-54.
25. Shimizu N et al. Squamous cell carcinoma of bladder producing granulocyte colony-stimulating factor (G-CSF): a case report. Hinyokika Kiyo 2005;51(2):121-4.
26. Asano T et al. Bladder cancer producing granulocyte colony-stimulating factor (G-CSF): a case report. Hinyokika Kiyo 2002;48:495-8.
27. Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 2007;12 Suppl 2:22-6.
28. Takami K et al. Granulocyte-colony stimulating factor-producing pancreatic cancer: Report of a case. Surg Today 2008;38:453-7.
29. Pegram MD et al. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
30. Kynast B et al. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 1993;119:249-52.
31. Kern JA et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-7.
32. De Vita F et al. Increased serum levels of tumor necrosis factor-alpha are correlated to soluble intercellular adhesion molecule-1 concentrations in non-small cell lung cancer patients. Int J Mol Med 1998;1:605-8.
33. Wittig BM et al. Soluble E-selectin enhances intercellular adhesion molecule-1 (ICAM-1) expression in human tumor cell lines. Exp Cell Res 1997;237:364-70.
34. Darom A et al. Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients. World J Gastroenterol 2006;12:1924-32.
35. Chung YM et al. Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer 2005;117:194-201.
36. Brandacher G et al. Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 2006;7:599-612.
37. Hastie C et al. Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J Biol Chem 2008;283:12595-603.
38. Majima T et al. Interleukin-10 and interferon-gamma levels within the peritoneal cavity of patients with gastric cancer. J Surg Oncol 2001;78:124-30; discussion 131.
39. Voronov E et al. Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 2007;601:265-70.
40. Honegger AE et al. Interleukin-1 beta, transforming growth factor beta 1, prostaglandin E2, and fibronectin levels in the conditioned mediums of bone marrow fibroblast cultures from lung and breast cancer patients. Ann Hematol 2002;81:80-5.
41. Forones NM et al. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 2001;48:1199-201.
42. Saito H et al. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer. Surg Today 1998;28:1115-7.
43. Izzo F et al. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Ann Surg Oncol 1999;6:178-85.
44. Murakami S et al. Serum Soluble Interleukin-2 Receptor Levels in Patients with Breast Cancer. Breast Cancer 1997;4:25-28.
45. Bien E et al. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 2008;13:1-26.
46. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
47. Eklund JW et al. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004;16:542-6.
48. Bubenik J. Interleukin-2 therapy of cancer. Folia Biol (Praha) 2004;50:120-30.
49. Todaro M et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402.
50. Lee SO et al. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008;68:85-91.
51. Takeshi U et al. Interleukin-4 in patients with prostate cancer. Anticancer Res 2005;25:4595-8.
52. Baleeiro RB et al. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol Immunother 2008;57:1335-45.
53. Culig Z et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497-505.
54. Duffy SA et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008. (Epub ahead of print).
55. Tas F et al. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24:492-6.
56. Veltri RW et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999;53:139-47.
57. Kocak H et al. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Biochem 2004;37:673-8.
58. Galizia G et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 2002;22:473-82.
59. Santin AD et al. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001;108:804-8.
60. De Vita F et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000;117:365-73.
61. Naugler WE et al. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14:109-19. Heikkilä K et al. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 2008;44:937-45.
62. Knüpfer H et al. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007;102:129-35.
63. Naumnik W et al. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst 2004;49:246-51.
64. Merendino RA et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 2001;16:126-9.
65. Vidal-Vanaclocha F et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006;25:417-34.
66. Lu Y et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006;66:1311-8.
67. Penson RT et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41.
68. Islekel H et al. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 2007;25:433-41.
69. Kiersnowska-Rogowska B et al. Estimation of level of soluble form PECAM-1, ICAM-2 and TNF-alpha, IL-18 in serum patients with chronic myelogenic leukemia. Przegl Lek 2005;62:772-4.
70. De Jaeger K et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1378-87.
71. Shariat SF et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992-9.
72. Ivanovic V et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003;39:454-61.
73. Santin AD et al. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001;108:804-8.
74. Dong W et al. Expression and significance of serum soluble tumor necrosis factor receptor-I in patients with head and neck neoplasm. Zhonghua Er Bi Yan Hou Ke Za Zhi 2001;36:468-70.
75. Sulkowska M et al. Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer. Tumori 2006;92:67-71.
76. Naor D et al. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79.
77. Wineland AM et al. Modern methods to predict costs for the treatment and management of head and neck cancer patients: examples of methods used in the current literature. Curr Opin Otolaryngol Head Neck Surg 2008;16:113-6.
78. Tesarova P et al. Soluble adhesion molecules in female patients with breast carcinoma. Cas Lek Cesk 2003;142:292-9.
79. Mayer S et al. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 2008. (Epub ahead of print).
80. Subramaniam V et al. Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp Mol Pathol 2007;83:341-6.
81. Harn HJ et al. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 1996;22:107-10.
82. Heath-Engel HM et al. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 2008;27:6419-33.
83. Ashkenazi A et al. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
84. Wagner KW et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7.
85. Kim R et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100:2281-91.
86. Hori T. Roles of OX40 in the pathogenesis and the control of diseases. Int J Hematol 2006;83:17-22.
87. Vereecken P et al. High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Derm 2005:31;105-9.
88. Sardana G et al. Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Culture–Conditioned Medium. Clinical Chemistry 2007;53: 429-437.
89. Park YP et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer 2007;120:813-20.
90. Iacovazzi PA et al. Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results. Int J Biol Markers 2003;18:222-6.
91. Moreaux J et al. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer 2009;9:83.
92. Planelles L et al. The expanding role of APRIL in cancer and immunity. Curr Mol Med 2008;8:829-44.
93. Kren L et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12:44-9.
94. Herszényi L et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008;8:194.
95. Jean D et al. Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene 2006;25:1474-84.
96. Hashimoto Y et al. Significance of 32-kDa cathepsin L secreted from cancer cells. Cancer Biother Radiopharm 2006;21:217-24.
97. Contini P et al. In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand. Leukemia 2007;21:253-60.
98. Schwarzmeier JD et al. Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005;46:157-65.
99. Barna G et al. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol 2008;26:167-70.
100. Ranheim EA eta l. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;12:3556-65.
101. Widney D et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Ckin Immunol 1999;93:114-23.
102. Lens SM. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998;10:491-9.
103. Osaka A et al. A novel role of serum cytochrome c as a tumor marker in patients with operable cancer. J Cancer Res Clin Oncol 2009;135:371-7.
104. Osaka et al. Serum cytochrome c to indicate the extent of ongoing tumor cell death. Int J Lab Hematol 2008. [Epub ahead of print]
105. Wan X et al. DcR3/TR6 modulates immune cell interactions. J Cell Biochem 2003 ;89 :603-12.
106. Udupa KB. Functional significance of erythropoietin receptor on tumor cells. World J Gastroenterol 2006;12:7460-2.
107. Okazaki T et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008;10:932-9.
108. Bruserud O et al. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels. Cancer Immunol Immunother 2000;49:377-87.
109. Maecker HL et al. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002;2:139-48.
110. Ryan AE et al. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 2006;5:246-9.
111. Persano L et al. Interferon-{alpha} Counteracts the Angiogenic Switch and Reduces Tumor Cell Proliferation in a Spontaneous Model of Prostatic Cancer. Carcinogenesis 2009. [Epub ahead of print]
112. Roy R et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008;14:6610-7.
113. Nielsen BS et al. Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS ONE 2008;3:e2959.
114. Zhang B et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008;8:83.
115. Laack E et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 2005;50:51-8.
116. Yang SF et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354:91-9.
117. Ishida H et al. Determining the levels of matrix metalloproteinase-9 in portal and peripheral blood is useful for predicting liver metastasis of colorectal cancer. Jpn J Clin Oncol 2003;33:186-91.
118. Tas F et al. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol 2008;25:431-6.
119. Adzić M et al. Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients. J BUON 2004;9:283-7.
120. Psyrri A et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Ann Oncol 2007;18:709-15.
121. Garcia J et al. P-selectin mediates metastatic progression through binding to sulfatides on tumor cells. Glycobiology 2007;17:185-96.
122. Lewis CE et al. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 2007;67:8429-32.
123. Martin V et al. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 2008;23:773-80.
124. Würtz SO et al. TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol 2008;47:580-90.
125. Hornebeck W et al. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 2005;87:377-83.
126. Culhaci N et al. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer 2004;4:42.
127. Frederiksen C et al. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 2009;29:75-81.
128. Toiyama Y et al. Circulating form of human vascular adhesion protein-1 (VAP-1): Decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis. J Surg Oncol 2009;99:368-372.
129. Kawano T et al. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am J Otolaryngol 2005;26:308-13.
130. Ding YB et al. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2003;9:1409-14.
131. Silva HC et al. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 2006;53:538-43.
